SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced that the pivotal clinical study of Polidocanol, conducted in Germany by BioForm Medical's partner, Chemische Fabrik KREUSSLER & Co. GmbH (Kreussler), successfully met the study primary endpoint and has been submitted to FDA as part of a New Drug Application (NDA) process.

SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2008. Net sales were $16.7 million for the quarter ended June 30, 2008 as compared to $15.4 million for the quarter ended June 30, 2007, an increase of $1.3 million or 8.4%. The net loss was $20.0 million for the quarter ended June 30, 2008 as compared to a net loss of $4.9 million for the quarter ended June 30, 2007. Net sales were $67.5 million for fiscal year 2008 as compared to $47.4 million for fiscal year 2007, an increase of $20.1 million or 42.4%. The net loss was $29.5 million for the fiscal year 2008 as compared to $13.6 million for fiscal year 2007. The $20.0 million net loss in the fourth quarter and the $29.5 million net loss for fiscal year 2008 each included an $11.2 million charge for acquired in-process research and development arising from the purchase of substantially all assets of Advanced Cosmetic Intervention, Inc. (ACI) in April 2008.

SAN FRANCISCO, Sept. 1 /PRNewswire/ -- As baby boomers age, varicose veins can signal health concerns of not merely unsightly veins, but sometimes painful ulcers that can be a harbinger of a potential for stroke. Fortunately, a fairly simple procedure of laser surgery exists that can reduce the risk of serious complications.

SAN MATEO, Calif., Aug. 22 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) announced that on Thursday, September 4, 2008, it will report its financial results for its fourth quarter and fiscal year ended June 30, 2008. The Company will issue the earnings press release after the NASDAQ Global Market closes and will hold a conference call with investors at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

CHICAGO, July 29 /PRNewswire/ -- Varicose veins -- unsightly bulging veins in the legs -- force many embarrassed sufferers to cover up, even on the hottest summer days. While often dismissed as a cosmetic issue, varicose veins actually can develop into serious health problems. According to a new survey, many who suffer from varicose veins aren't aware of this and are not seeking treatment for their condition. The survey, sponsored by Vein Clinics of America, found that one in five people reported having varicose veins, and half (48 percent) also experienced aching pain in the legs. Surprisingly, most people (87 percent) reported they have never sought treatment and nearly half (42 percent) do not consider varicose veins to be a serious health issue.

SAN MATEO, Calif., June 26 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced the publication of five studies in the June 2008 issue of the Journal of Dermatologic Surgery, a peer-reviewed publication of the American Society of Dermatologic Surgery. The five published clinical and preclinical reports were:

SAN MATEO, Calif., June 26 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced the publication of five studies in the June 2008 issue of the Journal of Dermatologic Surgery, a peer-reviewed publication of the American Society of Dermatologic Surgery. The five published clinical and preclinical reports were:

SAN MATEO, Calif., June 26 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced the publication of five studies in the June 2008 issue of the Journal of Dermatologic Surgery, a peer-reviewed publication of the American Society of Dermatologic Surgery. The five published clinical and preclinical reports were:

SAN MATEO, Calif., June 20 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) today announced that Steven Basta, Chief Executive Officer of BioForm Medical will present a company overview at the upcoming Jefferies Second Annual Healthcare Conference being held June 24-26th, 2008 in New York. BioForm Medical's presentation will take place on Wednesday, June 25th, 2008 at 8:30 a.m. EDT.

ATLANTA and SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), and BioForm Medical, Inc. (Nasdaq: BFRM) today announced that they have received a CE Mark for the use of CryoLife's BioGlue Surgical Adhesive for periosteal fixation following endoscopic browplasty or brow lift, a reconstructive plastic surgery procedure. The CE Mark approval allows the product to be marketed in the European Community (EU).